Our affiliates:


Nike Sweatshirts Green

´╗┐AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib ABT

4Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early onset breast cancer. J Natl Cancer Inst. 1999;91(11):943 9.

It is estimated that at least five percent of breast cancer cases result from inherited mutations or alterations in the BRCA1 and BRCA2 breast cancer susceptibility genes.3,4 Women with these mutations have a 40 to 85 percent lifetime risk of developing breast cancer. Additionally, men with BRCA2 mutations Nike Grey Tracksuit Womens

About AbbVie Oncology

Nike Sweatshirts Green

AbbVie is a global, research based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.

Nike Sweatshirts Green

Nike Sweatshirts Green

is a naturally occurring enzyme in the body that repairs damage to DNA, and in certain types of cancers, repairs cancer cells. Discovered and developed by AbbVie researchers, veliparib is being developed to help prevent DNA repair in cancer cells and increase the effectiveness of common DNA damaging therapies like chemotherapy or radiation. Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase III studies in non small cell lung cancer and breast cancer.

"Our Phase III program for veliparib represents an innovative approach to developing this type of anti cancer compound. "This is the third Phase III trial evaluating the efficacy and safety of veliparib, and the second evaluating the addition of veliparib to chemotherapy for the treatment of patients with difficult to treat forms of breast cancer."

Nike Sweatshirts Green

Nike Sweatshirts Green

therapies that work against the processes cancers need to survive. By investing in new technologies and approaches, we are breaking ground in some of the most widespread and difficult to treat cancers, including multiple myeloma and chronic lymphocytic leukemia. Our oncology pipeline includes multiple new molecules in clinical trials being studied in more than 15 different cancers and tumor types.

Nike Sweatshirts Green

Nike Sweatshirts Green

About AbbVie

Nike Sweatshirts Green

Nike Sweatshirts Green

AbbVie oncology research is focused on the discovery and development of targeted Nike Sweatshirt Pocket On Sleeve

Breast cancer is the second most common cancer in the world and the most commonly diagnosed cancer in women worldwide.1 The HER2 gene, which normally helps cells in the breast remain healthy and function normally, can play a role in the development of breast cancer. Specifically, in approximately 25 percent of breast cancers, the HER2 gene does not work properly, causing cells in the breast to grow and divide in an uncontrolled way. This process, known as HER2 gene amplification or overexpression, results in HER2 positive breast cancer. HER2 positive breast cancers tend to grow faster, metastasize more quickly and are more likely to recur, compared to patients diagnosed with HER2 negative breast cancer.2

The randomized, double blind, Phase III clinical trial will recruit approximately 270 patients. The primary efficacy outcome of Nike Sweatshirts Green the trial is progression free survival (PFS). The secondary pre specified outcome measures include overall survival (OS), clinical benefit rate (CBR), objective response rate (ORR) and duration of response (DOR). PARP Nike Jackets Mens Red

3 American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.

About HER2 Breast Cancer

carry an increased risk of breast cancer.5

Information contained on this page is provided by an independent third party content provider. WorldNow and this Station make no warranties or representations in connection therewith. Specifically, the combination of veliparib, carboplatin and paclitaxel will be compared to treatment with carboplatin, paclitaxel and placebo in patients with human epidermal growth factor receptor 2 (HER2) negative metastatic or locally advanced breast cancer, containing BRCA1 and/or BRCA2 gene mutations.

About BRCA1 and BRCA2 Gene Mutation

Nike Sweatshirts Green

Nike Sweatshirts Green

Nike Hoodies For Men

Nike Jacket For Men Black

Converse For Boys
Converse Maroon High Cut
Nike Tracksuit For Boys

Nike Hoodie Black Womens

Nike Hoodie With Big Nike Logo

Nike Joggers Suits

Converse Womens Trainers
Nike Tracksuit Cream

Nike Pullover Hoodie Grey

Nike Jackets On Sale

Converse Kids White
Nike Windrunner Navy Blue

Converse Navy Blue High Tops

Home / Nike Sweatshirts Green